IMPORTANCE Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features remain largely unknown.
M alignant mesothelioma is a rare aggressive neoplasm arising from the pleural, peritoneal, or pericardial lining. Approximately 3000 new cases present annually in the United States. 1 Most mesotheliomas arise from the pleura, but 10% develop in the peritoneum. 2 Despite various treatment modalities (cytoreductive surgery, radiation, and hyperthermic intraoperative/adjuvant chemotherapy), 3 patients with mesothelioma have a poor prognosis. 4 Mesothelioma is associated with exposure to asbestos, less commonly with therapeutic radiation for prior malignant neoplasms and BAP1 tumor predisposition syndrome. [5] [6] [7] However, in cases without an identifiable cause, the pathogenesis remains unknown. Cytogenetically, 40% to 70% of both pleural and peritoneal mesotheliomas harbor loss of 9p including CDKN2A or 22q including NF2. 8, 9 Whereas somatic mutations in CDKN2A, BAP1, NF2, and SETD2 have been commonly identified in pleural mesothelioma, 8 molecular features of peritoneal mesothelioma remain largely unknown.
After encountering 1 index case of peritoneal mesothelioma harboring ALK rearrangement, we systematically investigated the presence of ALK alterations in a large series of 88 patients with peritoneal mesothelioma and characterized the mutational landscape of these tumors.
Methods
This study was approved by the institutional review board of the Brigham and Women's Hospital. We reviewed clinicopathologic characteristics and performed immunohistochemistry for ALK in all peritoneal mesotheliomas retrieved from the archives of Brigham and Women's Hospital (eTable 1 in the Supplement). In ALK-positive cases, ALK rearrangement was confirmed by FISH (eMethods in the Supplement). Anaplastic lymphoma kinase fusion partners were identified using 2 next generation sequencing platforms targeting tumor DNA (OncoPanel) and RNA (AMP translocation) (eMethods in the Supplement). In select cases, we quantified asbestos fibers by combined scanning electron microscopy and x-ray spectroscopy (eMethods in the Supplement). Immunohistochemistry for ALK was also performed in 205 pleural mesotheliomas (eMethods in the Supplement).
Results

Identification and Characterization of ALK Rearrangements
The characteristics of the study group are detailed in eResults in the Supplement. Screening the cohort using immunohistochemistry for ALK, we identified 3 cases of peritoneal mesothelioma with strong and diffuse cytoplasmic expression (eFigure 1A in the Supplement), 8 cases with focal and weak expression (eFigure 1B in the Supplement), and the remaining 77 cases were lacking ALK expression. In contrast, all pleural mesotheliomas were ALK-negative, consistent with published sequencing results. 8 We explored the molecular features of the ALK-positive peritoneal mesotheliomas.
In all 3 cases with diffuse strong ALK expression, FISH confirmed the presence of ALK rearrangements (eFigure 1C in the Supplement). In contrast, in the cases with focal weak ALK expression (7 cases with available material), no bona fide ALK rearrangements were found, by FISH (4 cases) or targeted next generation sequencing (OncoPanel, 3 cases). Instead, peritoneal mesotheliomas with focal weak ALK expression displayed an abnormal FISH pattern indicative of polysomy for the corresponding region of 2p23 (eFigure 1D in the Supplement). The ALK-negative cases had no ALK rearrangements.
Using targeted next generation sequencing of both tumor DNA and RNA, we identified novel ALK fusion partners: STRN, ATG16L1, and TPM1 in 1 case each of the ALKrearranged peritoneal mesotheliomas ( Figure 1) . The presence of STRN-ALK translocation has been rarely reported in carcinomas. 10 To our knowledge, ATG16L1-ALK fusion has not been described to date; whereas TPM1-ALK fusion has been uncommonly described in bladder carcinomas. 11 The ALK breakpoint was mapped to intron 19 in all 3 cases, the breakpoint of STRN to intron 3 ( Figure 1A ), the breakpoint of ATG16L1 to intron 2 ( Figure 1B) , and the breakpoint of TPM1 to the beginning of exon 9 ( Figure 1C ). Both STRN-ALK and TPM1-ALK fusions were in-frame alterations, predicted by DNA sequencing and confirmed by RNA sequencing ( Figures 1A and C) . For the ATG16L1-ALK fusion, RNA sequencing demonstrated a 122-base-pair insertion leading to an in-frame fusion between ATG16L1 and ALK ( Figure 1B ). In this case, karyotyping demonstrated t(2;2)(p23;q35), confirming rearrangement of ALK at 2p23 (eFigure 2 in the Supplement).
ALK-rearranged peritoneal mesothelioma lacked a history of therapeutic radiation, had multiple confluent peritoneal nodules (eFigure 3A in the Supplement), showed a tubulopapillary or solid histology (eFigure 3 in the Supplement), expressed mesothelial markers (keratin AE1/AE3, calretinin, and WT1), and retained BAP1 expression (eFigure 4 and eTable 2 in the Supplement). Ultrastructural studies in 2 available cases demonstrated apical microvilli and numerous desmosomes, confirming a mesothelial phenotype (eFigure 5 in the Supplement). No asbestos fibers were detected in any of the ALKrearranged cases by combined scanning electron microscopy and x-ray spectroscopy. 12 Furthermore, the typical loss of chromosomal region 9p or 22q was not detected in any of ALKrearranged cases using FISH or karyotyping. All 3 ALKrearranged peritoneal mesotheliomas lacked molecular alterations in BAP1, SETD2,orNF2 that are typically present in other peritoneal mesotheliomas ( Figure 2 ). No significant difference in overall survival was noted with age, history of therapeutic radiation, tumor histology, or BAP1 expression (eResults, eTable 3, and eFigure 6 in the Supplement). Although overall survival was not affected by the presence of ALK rearrangement (present vs absent; HR, 0.5; 95% CI, 0.1-1.8; P = .29) or ALK protein expression (present vs absent; HR, 1.5; 95% CI, 0.6-4.2; P = .40), patients with weak focal ALK expression have a shorter overall survival than patients with absent or diffuse strong ALK expression (median survival, 4.8, 38.4, and 79.2 months, respectively; 3-way analysis, P = .03) (eResults and eFigure 7 in the Supplement).
Discussion
Oncogenic fusions of ALK to diverse partners have been reported in carcinomas, mesenchymal tumors, and lymphomas. 10, 11, 13 In some ALK-rearranged tumors, ALK is a 
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Heat map comparing the distribution of recurrent single nucleotide and copy number variations in ALK-rearranged peritoneal mesotheliomas (cases 1-3) and peritoneal mesotheliomas with no ALK rearrangement (cases 4-9) using targeted next generation DNA sequencing. Peritoneal mesotheliomas with ALK rearrangements comprise a distinct genetic cluster lacking the most common molecular alterations typically found in peritoneal mesotheliomas (BAP1, SETD2, and NF2). E indicates epithelioid mesothelioma; B, biphasic mesothelioma. ALK exon 20 STRN exon 3
ALK exon 20 pivotal therapeutic target. 14 However, the ALK status in mesotheliomas remains unexplored. Recently, ALK rearrangement has been described in 1 pediatric peritoneal mesothelioma, although the fusion partner was not investigated. 15 
Limitations
Although most studies have not found ALK rearrangement in mesotheliomas, this may be owing to the tumor location (pleural vs peritoneal) and the magnitude of the study cohort. Our study was limited by the low incidence of peritoneal mesothelioma and the low prevalence of patients with ALK rearrangement. Larger multiinstitutional prospective studies are needed to confirm our correlative findings and explore the efficacy of ALK-targeted therapy. Genome-wide analysis of 216 pleural mesotheliomas has found no ALK-rearranged cases. 8 Indeed, our study did not identify any ALK-positive pleural mesotheliomas. In contrast, in peritoneal mesothelioma, we identified ALK rearrangements in 3 of 88 (3%) patients, including 2 of 8 (25%) women under 40, suggesting that ALK rearrangement may be more prevalent in young women with peritoneal mesothelioma. We identified (1) the precise ALK breakpoints by DNA sequencing, (2) the in-frame mutant ALK fusion transcripts by RNA sequencing, and (3) ALK protein overexpression by immunohistochemistry, which together strongly suggest that the ALK alterations uncovered in this study represent functional and clinically-actionable alterations ( Figure 1 ) (eFigure 1A and eFigure 8 in the Supplement). Furthermore, ALK-rearranged cases lacked asbestos fibers, a history of therapeutic radiation, and loss of chromosomal region 9p or 22q or the genetic alterations in BAP1, SETD2,orNF2 that are typically present in peritoneal mesothelioma ( Figure 2 ). Our findings suggest that oncogenic ALK fusion may represent a novel causation mechanism for a subset of patients with peritoneal mesothelioma. These patients can be readily identified using ALK immunohistochemistry and triaged toward a personalized targeted treatment.
Conclusions
We identified ALK rearrangements in 3% of patients with peritoneal mesotheliomas that (1) present in younger women, (2) lack asbestos fibers, (3) have no history of radiation exposure, and (4) lack the typical genetic abnormalities present in peritoneal mesothelioma. We describe clinically actionable ALK rearrangements as a novel pathogenetic mechanism in a subset of peritoneal mesotheliomas with promise for targeted therapy. 
ARTICLE INFORMATION
SUPPLEMENTAL ONLINE CONTENT eMETHODS Patient Selection
We identified 88 consecutive patients with available tissue material (formalin-fixed paraffin embedded blocks or unstained slides) who were diagnosed with diffuse malignant peritoneal mesothelioma at the Brigham and Women's Hospital, Boston, MA, between January 2005 and December 2015. The group was identified from surgical pathology and consultation archival files at our institution using keyword searches ("mesothelioma"), ICD9 code (158.9), and ICD10 code (C45.1, C48.2). We included only primary diffuse malignant peritoneal mesothelioma and excluded (1) cases originating in the pleura, pericardium, or tunica vaginalis, (2) cases with a prior diagnosis of pleural mesothelioma, and (3) cases diagnosed as atypical mesothelial proliferation, well-differentiated papillary mesothelioma, or localized peritoneal mesothelioma. The clinical and demographic characteristics are presented in eResults and eTable 1. This study was approved by the Institutional Review Board.
Assessment of Peritoneal Mesothelioma
Histology, Karyotyping, and Fluorescence in Situ Hybridization for Chromosomal 9p and 22q loss. For each patient, we reviewed an average of 12 (median 2, range 1 to 90) hematoxylin and eosin-stained slides and 8 (median 6, range 0 to 47) immunohistochemical stains for diagnostic work-up. Tumors were classified into epithelioid, biphasic, or sarcomatoid types according to WHO criteria. 1 To assess for chromosomal 9p and 22q loss, karyotype and/or FISH testing were performed in select cases as detailed previously. 2 The immunophenotypic and cytogenetic characteristics are presented in eResults and eTable 2.
Electron Microscopy. In a subset of cases, electron microscopy was performed for diagnostic work-up as described previously. 3, 4 Fresh tissue was fixed in 2% glutaraldehyde, post-fixed in 1% osmium tetroxide, dehydrated, and embedded in epoxy resin. One-µm-thick sections were cut and stained with toluidine blue, followed by cutting of ultrathin sections that were stained with uranyl acetate-lead citrate.
Asbestos Fibers Quantification. In select cases, we quantified asbestos fibers by performing combined scanning electron microscopy (SEM) and energy dispersive X-ray spectroscopy (EDS) on formalin-fixed paraffinembedded tissue blocks as previously described. 5 After removing block surface (of approximately 50µm) with stainless steel blades to minimize contamination, the tissue blocks were mounted on SEM aluminum M4 stub with low temperature glue (16068; Ted Pella, Redding, CA), with backscattering images acquired using a Hitachi SU6600 field emission scanning electron microscope (Hitachi, Tokyo, Japan) and EDS spectra acquired using the X-Max 50 Silicon Drift Detector and Oxford Aztec 3.1b software (Oxford Instruments, Concord, MA). EDS were calibrated using spinel (MgAl 2 O 4 ) and pure copper for peak position accuracy.
ALK Immunohistochemistry and FISH
Immunohistochemistry for ALK was performed on 4-µm-thick formalin-fixed paraffin-embedded whole tissue sections in 88 cases of peritoneal mesothelioma following pressure cooker heat-induced antigen retrieval at 1:50 dilution using the clone 5A4 (Leica Biosystems, Danvers, MA).
In addition, immunohistochemistry for ALK was performed in 205 cases of pleural mesothelioma on 4-µm-thick formalin-fixed paraffin-embedded tissue microarrays, constructed as triplicate cores of 0.7 mm in diameter for each case; for these cases, all without preoperative chemotherapy, patients were consented for an Institutional Review Board-approved bio-repository database (Dana Farber/Harvard Cancer Center protocol #98-063). 6, 7 For peritoneal mesothelioma cases showing ALK expression, ALK rearrangement was confirmed by FISH testing (Vysis LSI ALK Dual color, Break Apart Rearrangement Probe, Abbott Molecular, Abbott Park, IL) as described. 8 
Identification of ALK Fusion Partners
To confirm ALK rearrangement and identify the ALK fusion partners in the tumor samples, we utilized two clinically validated next generation sequencing (NGS) assays.
Targeted Next Generation DNA Sequencing. For tumor DNA sequencing, targeted next generation sequencing (OncoPanel) of 113 introns from 35 genes for rearrangement and 305 cancer-associated genes was performed using DNA extracted from formalin-fixed paraffin-embedded tissue, Agilent SureSelect hybrid capture kit, and Illumina HiSeq 2500 (San Diego, CA) sequencer as previously described. 9 The complete gene list interrogated was previously published. 10 Data were processed using an internally developed bioinformatics pipeline/algorithms; sequence reads were annotated using Integrated Genome Viewer (Broad Institute, Cambridge, MA). Individual variants were interpreted based on tumor percentage, read depth, and alteration complexity. Evaluation for overall mutational burden and the presence of microsatellite instability (MSI) was performed using algorithms developed in-house as previously described.
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Anchored Multiplex PCR (AMP) and Next Generation Sequencing. For targeted fusion transcript detection of tumor RNA, we performed Anchored Multiplex PCR (AMP) and next generation sequencing using Illumina MiSeq (San Diego, CA) as previously described. 12 Briefly, nucleic acid was reverse transcribed with random hexamers, followed by second-strand synthesis to create double-stranded complementary DNA to be end-repaired, adenylated, and ligated with a half-functional adapter; two hemi-nested PCR reactions using the ArcherDx FusionPlex Solid Tumor Kit primers (ArcherDx, Boulder, CO) were performed to create a sequencing library targeting specific exons. A laboratory-developed algorithm was used for fusion transcript detection and annotation.
Analysis and Fusion Depiction. The predicted gene fusion products were depicted using Illustrator for Biologic Sequences (http://ibs.biocuckoo.org) 13 and Exon-Intron Graphic Maker (http://wormweb.org/exonintron). The schematics of the predicted fusion proteins were depicted using Discovery Studio 2016 Visualizer v16 (Dassault Systèmes, Waltham, MA), with structural data obtained from Protein Data Bank (http://www.rcsb.org) on ALK catalytic domain (3LCT), 14 striatin (4N6J), 15 ATG16L1 (5D7G), 16 and TPM1 (3J8A).
17
Statistical Analysis
Categorical and numerical data were compared using chi square and unpaired t tests, respectively. Survival was defined as the time of pathologic diagnosis to the time of death from any cause or to the time of last clinical follow-up, at which point the survival data were censored. The prognostic significance of clinical and pathologic characteristics was determined using univariate Cox regression analysis. Statistical analyses were performed using GraphPad Prism version 5.02 and GraphPad InStat version 3.06 (www.graphpad.com, LaJolla, California, USA). Data were analyzed and reported in accordance with the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria. 18 
eRESULTS
Patient Characteristics
The current study included 39 men and 49 women, with a median age of 61 years (range, 17 to 84 years). Of 88 patients, 9 (10%) were under 40 years of age. Of 71 patients with available information on clinical presentation, 62 (87%) were symptomatic (commonly abdominal pain or bloating), while 9 (13%) cases were incidentally discovered radiologically or intraoperatively. A history of external beam radiation to the abdomen was documented in three patients: two patients had treatment of ovarian cancer 30 years prior, and one patient had treatment for non-Hodgkin lymphoma 37 years prior. One patient had a history of well-differentiated papillary mesothelioma of the peritoneum 13 years prior. A history of reported potential asbestos exposure was identified in 30 of 59 (51%) patients with available reported exposure data. Concurrent involvement of the pleura by pleural plaques was radiographically documented in 29 of 61 (48%) patients in their radiographic reports. Of 69 patients with available data on smoking status, 37 were never smokers (including two patients with ALK-rearranged peritoneal mesothelioma), 20 were former smokers, and 12 were current smokers (including one patient with ALKrearranged peritoneal mesothelioma). There was no statistically significant difference in the smoking status (never vs. former or current) among peritoneal mesothelioma patients with vs. without ALK rearrangement (P=0.64).
Of 86 patients with available treatment information, 46 (53%) underwent surgical debulking; 41 (47%) received systemic chemotherapy; 23 (26%), hyperthermic intraperitoneal chemotherapy (HIPEC); and 2 (2%), radiation; two patients expired before treatment initiation (eTable 1).
Histologic, Immunophenotypic, and Cytogenetic Characteristics
Diffuse malignant peritoneal mesothelioma presented as multiple tumor nodules involving the peritoneum, ranging from less than 1 cm to 23 cm (median 6 cm; size documented in 42 cases). A total of 114 specimens (48 core needle biopsies and 66 surgical resections) from 88 patients were reviewed. Histology was epithelioid in 80 patients (91%; 17 with prominent papillary architecture, 3 with myxoid features, 1 with round-cell morphology, and 1 lymphohistiocytic variant), biphasic in 6 patients (7%), and sarcomatoid in 2 patients (2%). Calretinin was expressed in 64 of 65 (99%), WT1 in 62 of 64 (97%), keratin cocktail AE1/AE3 in 52 of 53 (98%), and podoplanin (D2-40) in 32 of 40 (80%) cases. Loss of BAP1 expression was detected in 22 of 83 (27%) cases. Of 28 cases with available cytogenetics, loss of chromosome 9p (including CDKN2A which encodes the tumor suppressor p16
INK4a ) was detected in 11 (39%); loss of chromosome 22q was detected in 12 cases (43%), including concurrent loss of 9p and 22q in 8 cases (29%) (eTable 2).
Survival Analysis
Of 70 patients with available clinical follow-up, the median follow-up duration was 1.8 years, while the median overall survival time using censored data was 2.8 years. Univariate Mantel-Cox regression analysis showed that unfavorable prognostic factors for survival included male gender (P=0.034), loss of chromosome 9p (P=0.0002), and loss of chromosome 22q (P=0.044) (eFigure 6). No statistically significant difference in overall survival was noted with age (≤40 vs. >40 years; P=0.20), history of therapeutic radiation (P=0.45), tumor histology (epithelioid vs. non-epithelioid; P=0.11), or BAP1 expression (intact vs. loss; P=0.47) (eFigure 6). While overall survival was not affected by the presence of ALK rearrangement (present vs. absent; P=0.29) or ALK protein expression (present vs. absent; P=0.40), subgroup analysis demonstrated that patients with weak focal ALK expression have a significantly shorter overall survival than patients with absent or diffuse strong ALK expression (median overall survival times, 4.8 months, 38.4 months and 79.2 months, respectively, P=0.028) (eFigure 7). This may be explained by a significant correlation between mesotheliomas with weak focal ALK expression and simultaneous chromosomal loss involving both 9p and 22q (P=0.026).
Overall Mutational Burden in Peritoneal Mesothelioma
As assessed by targeted DNA next generation sequencing (OncoPanel), the overall mutational burden in the 9 peritoneal mesotheliomas (Figure 2 ) was 2.6-9.6 (median 7.9, average 6.7) per Mb (megabase), including 0.0-1.3 (median 1.2, average 0.7) single-base insertion or deletion mutations in repeat (INDELs) per Mb. The 3 ALKrearranged peritoneal mesotheliomas (cases #1-3) harbored an overall mutational burden of 4.8-9.6 (median 6.0, average 6.8) Mb, including 0.0-1.2 (median 1.2, average 0.8) INDELs per Mb; whereas the 6 peritoneal mesotheliomas with no ALK rearrangement (cases #4-9) harbored an overall mutational burden of 2.6-9.2 (median 8.2, mean 6.7) per Mb, including 0.0-1.3 (median 0.6, mean 0.6) INDELs per Mb. There was no statistically significant differences in the overall mutation burden (P=0.95) or the number of INDELs (P=0.71) between the two groups. Furthermore, the overall mutational burden and the number of INDELs per Mb were lower than established cutoff values, 11 concluding that there was no molecular evidence of mismatch repair deficiency or microsatellite instability in all 9 peritoneal mesotheliomas tested.
Structural Depiction of ALK Fusion Proteins in Peritoneal Mesothelioma
Using the DNA/RNA sequencing results (Figure 1 ) along with the structural data obtained from Protein Data Bank (http://www.rcsb.org) on ALK catalytic domain (3LCT), 14 striatin (4N6J), 15 ATG16L1 (5D7G), 16 and tropomyosin alpha 1 (3J8A), 17 we depicted the ALK fusion proteins identified in this study in eFigure 8. Consistent with the literature, 19 each of the resulting ALK fusion proteins harbors an N-terminal domain containing selfassociating polypeptides derived from the fusion partners (STRN, ATG16L1, and TPM1), as well as a constitutively active C-terminal tyrosine kinase domain of ALK. 
